10:04 AM
Dec 06, 2017
 |  BC Extra  |  Company News

FDA accepts Insys' NDA for buprenorphine sublingual spray

Insys Therapeutics Inc. (NASDAQ:INSY) said FDA accepted for review an NDA for the company’s buprenorphine sublingual spray to manage moderate...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >